億勝生物科技(01061.HK)2024年純利約3.07億港元 同比增加11.6%
格隆匯3月26日丨億勝生物科技(01061.HK)公告,截至2024年12月31日止年度,集團實現營業額約16.698億港元,較2023年減少3.9%。有關減少乃由於中國監管機構於製藥及醫療行業頒佈的若幹嚴厲政策和措施。然而,集團預期,當該等政策和措施爲人們所熟悉時,隨而來的不利局面將得到緩解。儘管營業額減少,集團仍實現純利約3.07億港元,同比增加11.6%。每股盈利54.14港仙。
爲應對該等挑戰,公司須在成本控制與品質保證間取得平衡。創新仍爲製藥企業發展的核心驅動力。爲保持競爭力,公司應:1.增加研發投入以培養創新人才,並加強與公私科研機構和大學的合作;2.注重技術創新,開發具有自主知識產權的產品;及3.探索新的商業模式和運營方式,提升創新效率。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.